293 related articles for article (PubMed ID: 37165384)
1. A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity.
Singh M; Kadhim MM; Turki Jalil A; Oudah SK; Aminov Z; Alsaikhan F; Jawhar ZH; Ramírez-Coronel AA; Farhood B
Cancer Cell Int; 2023 May; 23(1):88. PubMed ID: 37165384
[TBL] [Abstract][Full Text] [Related]
2. The Radioprotective Potentials of Silymarin/Silibinin Against Radiotherapy- Induced Toxicities: A Systematic Review of Clinical and Experimental Studies.
Latacela GA; Ramaiah P; Patra I; Jalil AT; Gupta R; Madaminov FA; Shaker Shafik S; Al-Gazally ME; Ansari MJ; Kandeel M; Mustafa YF; Farhood B
Curr Med Chem; 2023; 30(33):3775-3797. PubMed ID: 36424777
[TBL] [Abstract][Full Text] [Related]
3. The Radiosensitizing Potentials of Silymarin/Silibinin in Cancer: A Systematic Review.
Gupta J; Turki Jalil A; Al-Hawraa Riyad Muedii Z; Aminov Z; Alsaikhan F; Ramírez-Coronel A; Ramaiah P; Farhood B
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37921180
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities.
Hu LF; Lan HR; Li XM; Jin KT
Oxid Med Cell Longev; 2021; 2021():2951697. PubMed ID: 34471463
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Cardioprotective Effects of Curcumin against Doxorubicin-Induced Cardiotoxicity: A Systematic Review.
Zhang Q; Wu L
J Oncol; 2022; 2022():7277562. PubMed ID: 35237323
[TBL] [Abstract][Full Text] [Related]
6. The cardioprotective effects of nano-curcumin against doxorubicin-induced cardiotoxicity: A systematic review.
Moutabian H; Ghahramani-Asl R; Mortezazadeh T; Laripour R; Narmani A; Zamani H; Ataei G; Bagheri H; Farhood B; Sathyapalan T; Sahebkar A
Biofactors; 2022 May; 48(3):597-610. PubMed ID: 35080781
[TBL] [Abstract][Full Text] [Related]
7. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
[TBL] [Abstract][Full Text] [Related]
8. The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review.
Najafi M; Hooshangi Shayesteh MR; Mortezaee K; Farhood B; Haghi-Aminjan H
Life Sci; 2020 Jan; 241():117173. PubMed ID: 31843530
[TBL] [Abstract][Full Text] [Related]
9. The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review.
Rostamian S; Heidari-Soureshjani S; Sherwin CMT
Cent Nerv Syst Agents Med Chem; 2023; 23(2):86-94. PubMed ID: 37612866
[TBL] [Abstract][Full Text] [Related]
10. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block.
Kadoglou NPE; Panayiotou C; Vardas M; Balaskas N; Kostomitsopoulos NG; Tsaroucha AK; Valsami G
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631363
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer prevention by silibinin.
Singh RP; Agarwal R
Curr Cancer Drug Targets; 2004 Feb; 4(1):1-11. PubMed ID: 14965263
[TBL] [Abstract][Full Text] [Related]
15. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention.
Zhao J; Agarwal R
Carcinogenesis; 1999 Nov; 20(11):2101-8. PubMed ID: 10545412
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study.
Li WG; Wang HQ
J BUON; 2016; 21(4):917-924. PubMed ID: 27685914
[TBL] [Abstract][Full Text] [Related]
17. Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade.
Choi ES; Oh S; Jang B; Yu HJ; Shin JA; Cho NP; Yang IH; Won DH; Kwon HJ; Hong SD; Cho SD
Cell Oncol (Dordr); 2017 Jun; 40(3):235-246. PubMed ID: 28401485
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effect of silymarin nanoemulsion on 5-fluorouracil-induced cardiotoxicity in rats.
Safarpour S; Safarpour S; Moghadamnia AA; Kazemi S; Ebrahimpour A; Shirafkan F; Mansoori R; Golchoobian R
Arch Pharm (Weinheim); 2022 Jul; 355(7):e2200060. PubMed ID: 35411625
[TBL] [Abstract][Full Text] [Related]
19. Silymarin versus Silibinin: Differential Antioxidant and Neuroprotective Effects against H2O2-induced Oxidative Stress in PC12 Cells.
Jiang HH; Yan FS; Shen L; Ji HF
Nat Prod Commun; 2016 May; 11(5):633-6. PubMed ID: 27319137
[TBL] [Abstract][Full Text] [Related]
20. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis.
Singh RP; Tyagi AK; Zhao J; Agarwal R
Carcinogenesis; 2002 Mar; 23(3):499-510. PubMed ID: 11895866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
